| Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca |
| Recruiting | 4 | 99 | RoW | Dapagliflozin 10mg Tab, Forxiga 10mg, Lobeglitazone 0.5 mg, Duvie 0.5 mg, Dapagliflozin + Lobeglitazone, Forxiga 10mg + Duvie 0.5mg | Seoul National University Bundang Hospital | Diabetes Type 2 | 10/23 | 12/23 | | |
| Recruiting | 4 | 80 | RoW | Dapagliflozin | University of Campinas, Brazil | End-stage Kidney Disease | 11/24 | 12/24 | | |
NCT05735197: Effect of Dapagliflozin on Renal Outcomes and Bone Mineral Disease in Non-diabetic Chronic Kidney Disease Patients |
|
|
| Active, not recruiting | 4 | 100 | RoW | Dapagliflozin 10mg Tab, Dapagliflozin, Placebo, control | Mansoura University | Chronic Kidney Diseases, Bone Diseases, Metabolic | 11/23 | 01/24 | | |
| Recruiting | 4 | 120 | US, RoW | Pioglitazone 45 mg, Placebo | The University of Texas Health Science Center at San Antonio | Type 1 Diabetes Mellitus | 12/24 | 01/25 | | |
| Suspended | 4 | 250 | US | Dapagliflozin 10mg Tab | Albert Einstein Healthcare Network | Acute Kidney Injury, Percutaneous Coronary Intervention | 06/25 | 06/25 | | |
NCT03710460: Effect of Dapagliflozin/Metformin XR vs Monotherapies on Anthropometric Indicators in Obesity |
|
|
| Recruiting | 4 | 33 | RoW | Dapagliflozin, Forxiga, Dapagliflozin plus Metformin XR, XigDuo, Metformin XR | University of Guadalajara | Obesity | 12/23 | 12/23 | | |
ChiCTR2100049019: A single-center, prospective, double-blind, randomized controlled trial of dapagliflozin in improving ventricular remodeling in patients with left ventricular dysfunction after acute myocardial infarction |
|
|
| Not yet recruiting | 4 | 430 | | dapagliflozin is added to the conventional treatment ;the conventional treatment | Hunan Provincial People's Hospital; Hunan Provincial People's Hospital, Key Project of Hunan?provincial?science?and?technology?innovation | Acute Myocardial Infarction | | | | |
NCT05459701: Dapagliflozin in Type 2 Diabetes Mellitus Patients (T2DM) With Nonalcoholic Fatty Liver Disease (NAFLD) |
|
|
| Recruiting | 4 | 50 | RoW | Dapagliflozin 10mg Tab, Dapagliflozin 10 mg., Placebo | Rehab Werida, University of Alexandria | Nonalcoholic Fatty Liver Disease, Type 2 Diabetes | 04/24 | 05/24 | | |
NCT04783870: Effect of Dapagliflozin on LV Remodeling Post AMI |
|
|
| Recruiting | 4 | 60 | RoW | Dapagliflozin, Placebo | Instituto Mexicano del Seguro Social | Myocardial Infarction | 12/23 | 12/24 | | |
| Not yet recruiting | 4 | 1167 | NA | Canagliflozin, Dapagliflozin, Empagliflozin | Center for Outcomes Research and Clinical Epidemiology, Italy, Italian Society of Diabetology | Diabetes Mellitus, Type 2 | 12/23 | 12/23 | | |
ChiCTR2100052345: SGLT2 inhibitor regulates cardiomyocyte autophagy and interferes with light chain role and mechanism of type I cardiac amyloidosis |
|
|
| Not yet recruiting | 4 | 30 | | Dapagliflozin 10mg ;Dagglitazin simulant 10mg | Qilu Hospital of Shandong University; Qilu Hospital of Shandong University, Shandong Natural Science Foundation | cardiac amyloidosis | | | | |
ChiCTR2200064287: Effect and mechanism of dapagliflozin on patients with type 2 diabetes complicated with nonalcoholic fatty liver disease |
|
|
| Not yet recruiting | 4 | 72 | | dapagliflozin ;Other anti-diabetic drugs | Yuebei People's Hospital; Yuebei People's Hospita, self-raised | type 2 diabetes complicated with nonalcoholic fatty liver disease | | | | |
NCT04363697: Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68) |
|
|
| Recruiting | 4 | 2400 | US | Dapagliflozin, Placebo | The TIMI Study Group, AstraZeneca, Worldwide Clinical Trials | Acute Heart Failure, Heart Failure | 01/24 | 03/24 | | |
ADIDAS, NCT04707261: Association Between Dapagliflozin-induced Improvement and Anemia in Heart Failure Patients |
|
|
| Recruiting | 4 | 1990 | RoW | Dapagliflozin, FORXIGA, Placebo | Xiangtan Central Hospital, Second Xiangya Hospital of Central South University, ZhuZhou Central Hospital | Anemia, Heart Failure | 05/24 | 01/25 | | |
NCT05966818: Effect of Dapagliflozin in Non-Diabetic Patients With Nephrotic Syndrome. |
|
|
| Not yet recruiting | 4 | 90 | NA | Dapagliflozin and Standard therapy (ACEI or ARB)., Dapagliflozin (Diglifloz) 10 mg orally once daily and the standard therapy (ACEI or ARB)., Standard Therapy (ACEI or ARB)., Standard Therapy which include either ACEI or ARB. | Ain Shams University | Nephrotic Syndrome | 01/24 | 03/24 | | |
EPIDOTE, NCT03499704: A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by DPP-4 Inhibitor and Metformin Therapy |
|
|
| Active, not recruiting | 4 | 133 | RoW | Pioglitazone + Alogliptin, SYR-322-4833, Alogliptin, Metformin, Dapagliflozin | Celltrion Pharm, Inc. | Diabetes Mellitus, Type 2 | 01/24 | 06/24 | | |
| Completed | 4 | 117 | RoW | Dapagliflozin 10mg Tab, Sodium-glucose cotransporter-2 inhibitors | Cairo University, Aswan Heart Centre | Acute Heart Failure | 02/24 | 02/24 | | |
NCT06140537: Efficacy and Mechanisms of Dapagliflozin in Promoting Kidney Function and Cardiovascular Health in Kidney Transplant Recipients |
|
|
| Recruiting | 4 | 80 | US | Dapagliflozin 10mg Tab, Placebo | University of Colorado, Denver | Kidney Transplant; Complications, Vascular Diseases, Diabetes | 10/28 | 12/28 | | |
ChiCTR2200056968: A head-to-head study comparing the efficacy and safety of Tripterygium wilfordii polyglycosides and dagligosim in the treatment of diabetic nephropathy |
|
|
| Recruiting | 4 | 120 | | Tripterygium Glycosides ;Dapagliflozin | Yijishan Hospital of Wannan Medical College; Yijishan Hospital of Wannan Medical College, self-funded | diabetic nephropathy | | | | |
ChiCTR2300073720: Evaluation of the therapeutic effect of the SGLT-2 inhibitor dapagliflozin on non-alcoholic fatty liver disease |
|
|
| Not yet recruiting | 4 | 60 | | Patients received dapaglifozin 10 mg once daily for 3 months ;Patients received placebo once daily for 3 months | Jiangxi Provincial People's Hospital; Jiangxi Provincial People's Hospital, self-funded | non-alcoholic fatty liver disease | | | | |
| Recruiting | 4 | 50 | US | Dapagliflozin, Sodium-Glucose Cotransporter-2 (SGLT2) inhibitor, Placebo | Boston University, American Heart Association | Diabetes Mellitus, Type 2, Endothelial Dysfunction | 12/24 | 12/24 | | |
NCT06365541: The Efficacy and Safety of Dapagliflozin in Improving Heart Failure in Dialysis Patients |
|
|
| Recruiting | 4 | 40 | RoW | Dapagliflozin | The People's Hospital of Gaozhou | The Efficacy and Safety of Dapagliflozin in Improving Heart Failure in Dialysis Patients | 08/24 | 08/24 | | |
NCT06364930: SGLT2i to Prevent of Liver Complications in Patients With CHB and Diabetes Mellitus |
|
|
| Recruiting | 4 | 412 | RoW | Dapagliflozin 10mg Tab, Placebo 10mg Tab | Chinese University of Hong Kong | Chronic Hepatitis B | 10/30 | 03/31 | | |
| Recruiting | 4 | 12 | US | Sitagliptin, DPP4 inhibitor therapy, Dapagliflozin, SGLT2 inhibitor therapy, Placebo | Mayo Clinic | Lewy Body Dementia, Parkinson Disease | 06/24 | 06/24 | | |
NCT05743907: Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing Metformin Monotherapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control |
|
|
| Recruiting | 4 | 232 | RoW | DA-2811, Forxiga | Dong-A ST Co., Ltd. | Diabetes Mellitus | 12/24 | 12/24 | | |
CLIgAN, NCT04662723: Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy. |
|
|
| Recruiting | 4 | 878 | Europe | Corticosteroid, Methylprednisolone succinate, prednisolone, Renin-angiotensin sytem blockers, Ramipril, lisinopril, losartan, Sodium-glucose cotransporter 2 inhibitor, dapagliflozin, canagliflozin, empagliflozin | Fondazione Schena, University of Bari | Glomerulonephritis, Immunoglobulin A Nephropathy | 06/24 | 12/26 | | |
DAPA-TONIC, NCT06442280: SGLT-2 Inhibitor and High-Dose Furosemide Plus Small-Volume Hypertonic Saline Solution in Acute HF |
|
|
| Not yet recruiting | 4 | 544 | NA | Dapagliflozin tablet, SGLT2 inhibitor, Hypertonic Saline Solution, 1 Ml, Hypertonic Solution, Saline, Furosemide Injection, FUROSEMIDE | University of Palermo | Heart Failure Acute, Diabetes Type 2, Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction | 01/26 | 03/26 | | |
| Recruiting | 4 | 348 | RoW | Dapagliflozin, Placebo | Kun Hua | Atrial Fibrillation Recurrence, Cox Maze IV, Atrial Fibrillation, Patients With or Without Heart Failure and Diabetes | 06/24 | 08/24 | | |
DAPAMICRO, NCT05392959: Effect of the Antidiabetic Drug Dapagliflozin on the Coronary Macrovascular and Microvascular Function in Type 2 Diabetic Patients |
|
|
| Terminated | 4 | 4 | Europe | Dapagliflozin 10 mg Tab, Forxiga®, Placebo | Centre Hospitalier Universitaire Saint Pierre, AstraZeneca | Diabetes Mellitus, Type 2 | 07/23 | 07/23 | | |
ChiCTR2200063482: Effectiveness of SGLT2 inhibitors for cardiac remodeling after catheter ablation in atrial fibrillation patients with elevated natriuretic peptides: a prospective, open-label, randomized, blank-control trial |
|
|
| Not yet recruiting | 4 | 286 | | Conventional treatment and dapagliflozin ;Conventional treatment | Zhongshan Hospital, Fudan University; Zhongshan Hospital, Fudan University, Zhongshan Hospital Fudan University | Atrial fibrillation | | | | |
ChiCTR2200063258: The Effect of SGLT2 in atrial fibrillation recurrence and atrial remodeling after catheter ablation |
|
|
| Not yet recruiting | 4 | 200 | | dapagliflozin, 10mg qd po ;none | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, self-funded | atrial fibrillation | | | | |
DEFORM, NCT05848102: Dapagliflozin Effect on FunctiOnal Mitral Regurgitation and Myocardial Fibrosis |
|
|
| Recruiting | 4 | 166 | RoW | dapagliflozin | Sun Yat-sen University, First Affiliated Hospital, Sun Yat-Sen University, Third Affiliated Hospital, Sun Yat-Sen University, Second Affiliated Hospital of Guangzhou Medical University, Jieyang People's Hospital, Eighth Affiliated Hospital, Sun Yat-sen University, Affiliated Hospital of Guangdong Medical University, Yuebei People's Hospital, Zhongshan People's Hospital, Guangdong, China | Functional Mitral Regurgitation | 10/24 | 04/25 | | |
| Enrolling by invitation | 4 | 29 | US | Dapagliflozin 10mg Tab | Johns Hopkins University, University of California, Los Angeles, Brett Boyer Foundation, AstraZeneca | Heart Failure | 11/24 | 06/25 | | |
NCT05550441: Effect of Dapagliflozin on VT in Patients With Heart Failure. |
|
|
| Not yet recruiting | 4 | 120 | NA | Dapagliflozin, Placebo | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Heart Failure | 11/24 | 11/24 | | |
NCT05194592: Comparison of the Effects of Dapagliflozin and Gemigliptin on Ketone Metabolism and Cardiac Remodeling in Type 2 Diabetes |
|
|
| Recruiting | 4 | 122 | RoW | Dapagliflozin, Gemigliptin | Wonju Severance Christian Hospital | Type2 Diabetes, Remodeling, Ventricular | 12/24 | 06/25 | | |
ChiCTR2300067263: Efficacy and safety of dapagliflozin in adults with primary IgA nephropathy: a single-center, prospective, open, randomized controlled trial |
|
|
| Recruiting | 4 | 124 | | Dapagliflozin tablets 10mg once daily for 24 weeks + RAAS inhibitor at the maximum tolerable dose ;RAAS inhibitor at the maximum tolerable dose | Daping Hospital, Army Medical University; Daping Hospital, Army Medical University, Key Support Object of Outstanding Talent Pool of Army Characteristic Medical Center | IgA nephropathy | | | | |
NCT05782972: Therapeutic Response of Sodium-glucose Co-transporter Type-2 Inhibitor in Non-diabetic MAFLD Patients: a Pilot Study |
|
|
| Recruiting | 4 | 50 | RoW | dapagliflozin (Forxiga) | Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation | Metabolic Associated Fatty Liver Disease | 12/24 | 06/25 | | |
ChiCTR2300075232: To study the protective effect of dapagliflozin on perioperative myocardial injury/myocardial infarction in patients with chronic coronary syndrome complicated with diabetes mellitus undergoing elective PCI |
|
|
| Not yet recruiting | 4 | 624 | | NA ;NA | Beijing Hospital; Beijing Hospital, National High Level Hospital Clinical Research Funding | Chronic Coronary Syndrome | | | | |
NCT05443932: Dapagliflozin and Hydrochlorothiazide in Recurring Kidney Stone Patients |
|
|
| Not yet recruiting | 4 | 32 | Europe | Dapagliflozin, Hydrochlorothiazide | Medical University of Vienna | Urolithiasis, Hyperoxaluria | 12/24 | 12/25 | | |
ChiCTR2100046532: Study on the Correlation of dapagliflozin with Vitamin D, K2 in Diabetes Mellitus |
|
|
| Recruiting | 4 | 300 | | Metformin ;Dapagliflozin ;Metformin+Dapagliflozin | Weishan People's Hospital; Weishan People's Hospital, Self-raised | Type 2 Diabetes Mellitus | | | | |
NCT05788276: Can Dapagliflozin Preserve Structure and Function in Transplanted Kidneys? |
|
|
| Recruiting | 4 | 330 | Europe | Dapagliflozin 10mg Tab, Active, Placebo | Oslo University Hospital, St. Olavs Hospital, University Hospital of North Norway, Haukeland University Hospital | Kidney Transplant; Complications, Kidney Transplant Failure, Renal Failure | 03/25 | 06/28 | | |
ChiCTR2100045401: The comparative study of effects of liraglutide and dapagliflozin on cardiovascular diseas and brain function |
|
|
| Recruiting | 4 | 300 | | GLP-1 agonist ;SGLT-2 inhibitor ;Combination therapy | Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine; Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, self-funded | type 2 diabetes mellitus | | | | |
NCT05050500: The Effect of Dapagliflozin on the Short-term Prognosis of Patients With Acute Myocardial Infarction |
|
|
| Recruiting | 4 | 300 | RoW | Dapagliflozin 10mg/Tab, Dapagliflozin Group, Placebo, Placebo Group | Qingdao Central Hospital | Myocardial Infarction, Diabete Type 2, Glucose Intolerance | 09/25 | 01/26 | | |
ChiCTR2000037196: Effect of Dapagliflozin in Type 2 Diabetic Patients with Hyperfiltration: a Randomized Controlled Study |
|
|
| Recruiting | 4 | 600 | | Dapagliflozin 5mg tablet taken by mouth once daily for 2 years ;Placebo tablet taken by mouth once daily for 2 years | Shanghai General Hospital; Shanghai General Hospital, Shanghai Shenkang Hospital Development Center: Three-year Plan for Promoting Clinical Skills and Innovations in Municipal Hospitals | Type 2 Diabetic Patients With Hyperfiltration | | | | |
| Recruiting | 4 | 784 | Europe | Dapagliflozin 10 MG Oral Tablet [Farxiga], Farxiga, SGLT2i, Sodium glucose co-transporter-2 inhibitor, Placebo | Amsterdam UMC, ZonMw: The Netherlands Organisation for Health Research and Development | Acute Kidney Injury, Cardiac Surgery, Sodium-Glucose Transporter 2 Inhibitor | 08/25 | 10/25 | | |
| Active, not recruiting | 4 | 2067 | Europe | Metformin, Dapagliflozin 10 MG | Uppsala University, Uppsala University Hospital, Swedish Healthcare Regions, Swedish National Board of Health and Welfare, The Swedish National Diabetes Register | Type 2 Diabetes | 10/25 | 10/25 | | |
NCT06054035: SGLT2 Inhibition in Addition to Lifestyle Intervention and Risk for Complications in Subtypes of Patients With Prediabetes |
|
|
| Recruiting | 4 | 182 | Europe | Dapagliflozin (Forxiga®), Placebo matching Dapaglifolzin, Lifestyle Intervention | University Hospital Tuebingen, German Federal Ministry of Education and Research, German Center for Diabetes Research, AstraZeneca | Type2diabetes, PreDiabetes, Renal Failure | 03/26 | 12/26 | | |
| Not yet recruiting | 3/4 | 25 | | | Flinders Medical Centre, Flinders Medical Centre | Heart Failure | | | | |
2022-001262-35: Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 Dapagliflozin és hatása a szív- és érrendszeri eseményekre akut szívelégtelenségnél – myokardiális infarktus trombolízisénél 68 |
|
|
| Ongoing | 3/4 | 2400 | Europe | Dapagliflozin, Film-coated tablet | The Brigham and Women's Hospital, Inc., AstraZeneca Pharmaceuticals LP, Brigham and Women's Hospital | The study is evaluating the effect of In-hospital initiation of dapagliflozin in patients who have been stabilized during hospitalization for Acute Heart Failure A vizsgálat során a dapagliflozin kórházban történő elindításának hatását értékelik ki olyan betegeknél, akiket akut szívelégtelenség miatti kórházi kezelés során stabilizáltak., acute heart failure akut szívelégtelenségnél, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2008-004916-12: A 24-Week, International, Multi-centre, Randomised, Parallel-group, Double-blind, Active-controlled, Phase III study to Evaluate the Efficacy and Safety of Dapagliflozin in Combination with Metformin compared with a DPP-4 inhibitor (Sitagliptin) in Combination with Metformin in Adult Patients with Type 2 Diabetes who have Inadequate Glycaemic Control on Metformin Therapy Alone |
|
|
| Ongoing | 3 | 494 | Europe, RoW | Dapagliflozin, Sitagliptin, BMS-512148, A10BH01, Film-coated tablet, Over encapsulated tablet, Januvia, JANUVIA Tablets | AstraZeneca AB | Type 2 Diabetes Mellitus | | | | |
2015-004164-11: Effect of the glucose-lowering drug dapagliflozin on vascular function and blood pressure Effetto dell’antidiabetico orale dapagliflozin sulla funzione vascolare e sulla pressione arteriosa |
|
|
| Ongoing | 3 | 55 | Europe | FORXIGA, ESIDREX, NON DISPONIBILE, Film-coated tablet, Tablet, FORXIGA - 10 MG - COMPRESSE RIVESTITE CON FILM- USO ORALE - BLISTER CALENDARIZZATO (ALU/ALU) - 28 COMPRESSE, ESIDREX - 25 MG COMPRESSE 20 COMPRESSE | AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA, AstraZeneca S.p.A | Arterial hypertension Ipertensione arteriosa, Arterial hypertension Ipertensione arteriosa, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2016-003738-25: A 28-week, multi-center randomized, double-blind, placebo-controlled study to evaluate the potential of Dapagliflozin plus Exenatide in combination with high-dose intensive insulin therapy compared to Placebo in obese insulin-resistant patients with Type 2 Diabetes mellitus (Proof-of-concept study) Eine 28-wöchige, multizentrische, randomisierte, doppel-blinde, placebo-kontrollierte Studie zur Evaluation der Wirksamkeit von Dapagliflozin und Exenatid in Kombination mit einer hoch-dosierten intensivierten Insulintherapie im Vergleich zu Placebo bei adipösen insulin-resistenten Patienten mit Diabetes mellitus Typ 2 |
|
|
| Ongoing | 3 | 60 | Europe | Powder and solvent for suspension for injection, Film-coated tablet, Bydureon, Forxiga | University Medical Center Hamburg-Eppendorf, AstraZeneca GmbH | Obese insulin-resistant patients with Type 2 Diabetes mellitus (T2DM) and inadequate glycemic control (HbA1c ≥ 8.0% and ≤ 11.0%) Patienten mit Diabetes mellitus Typ 2 und inadäquater glykämischer Kontrolle (HbA1c ≥ 8.0% und ≤ 11.0%), Obese insulin-resistant patients with Type 2 Diabetes mellitus (T2DM) and inadequate glycemic control (HbA1c ≥ 8.0% and ≤ 11.0%) Patienten mit Diabetes mellitus Typ 2 und inadäquater glykämischer Kontrolle (HbA1c ≥ 8.0% und ≤ 11.0%), Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
2017-004709-42: Study to evaluate the effect of dapagliflozin, exenatide and their combination on the loss of protein in urine in patients with type 2 diabetes Studie naar het effect van dapagliflozine, exenatide en de combinatie van beiden op het verlies van eiwit via de urine bij patienten met diabetes type 2 |
|
|
| Ongoing | 3 | 17 | Europe | Forxiga, Bydureon, Film-coated tablet, Powder and solvent for prolonged-release suspension for injection, Forxiga, Bydureon | Martini Hospital, Astra Zeneca, Martini Hospital | Type 2 diabetes Diabetes mellitus type 2, Type 2 diabetes Suikerziekte, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
2017-004641-25: A rotation study of different albuminuria lowering drug classes to study individual drug response in diabetic and non diabetic Chronic Kideny Disease Uno studio che prevede la rotazione di piú farmaci che riducono l'albuminuria per valutare quale sia il miglior farmaco per il singolo paziente Estudio para evaluar la acción individal de diferentes clases de fármacos sobre la albuminuria en pacientes diabéticos y no diabéticos con enfermedad renal crónica |
|
|
| Ongoing | 3 | 46 | Europe | Dapaglifozin, Eplerenone, [na], Tablet, Forxiga, Eplerenone | University Medical Center Groningen, UNIVERSITY MEDICAL CENTER GRONINGEN, University Medical Center Groningen | Proteinuric Kidney disease Insufficienza Renale Cronica Proteinurica Enfermedad Renal Crónica Proteinúrica, Reduction in kidney function with increasing in protein in the urine Peggioramento della funzione renale con aumento delle proteine nelle urine Deterioro de la función renal con aumento de la proteinuria en orina, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2018-003442-16: DETERMINE-reduced – Dapagliflozin EffecT on ExeRcise capacity using a 6-MINutE walk test in patients with heart failure with reduced ejection fraction |
|
|
| Not yet recruiting | 3 | 300 | Europe | Dapagliflozin, Film-coated tablet, Forxiga | AstraZeneca AB, AstraZeneca AB | Heart Failure Patients with Reduced Ejection Fraction (HFrEF), Heart Failure with reduced pump function to eject blood flow, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2018-004120-11: Triple Therapy for Type 1 Diabetes with Insulin, Semaglutide and Dapagliflozin. |
|
|
| Ongoing | 3 | 114 | Europe | Ozempic, Forxiga, Not applicable, Solution for injection in pre-filled pen, Capsule, Ozempic, Forxiga | NHS Greater Glasgow and Clyde, University of Glasgow, , JDRF | Type 1 diabetes, Type 1 diabetes, Diseases [C] - Hormonal diseases [C19] | | | | |
NCT03842267: A Study to Evaluate the Efficacy and Safety of Gemigliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Dapagliflozin and Metformin (SOLUTION Study) |
|
|
| Completed | 3 | 315 | RoW | Gemigliptin 50mg, Gemigliptin Placebo | LG Chem | Diabetes Mellitus, Type 2 | 05/21 | 11/22 | | |
2020-003497-48: Empagliflozin and dapagliflozin for improvement of outcome in patients with acute heart failure |
|
|
| Not yet recruiting | 3 | 1364 | Europe | Tablet, Empagliflozin/Jardiance, Dapagliflozin/Forxiga | Medical University of Warsaw, Agencja Badań Medycznych (ABM) | acute decompensated heart failure, heart failure, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2021-004271-14: The effect of treatment with Dapagliflozin on heart and kidney function after catheter based aortic valve replacement for aortic stenosis EFFEKTEN AF BEHANDLING MED DAPAGLIFLOZIN PÅ HJERTE- OG NYREFUNKTIONEN EFTER KATETERBASERET AORTAKLAP-SUBSTITUTION FOR AORTASTENOSE |
|
|
| Not yet recruiting | 3 | 104 | Europe | Forxiga, Tablet | Aarhus University Hospital, department of Cardiology, Aarhus University Hospital | Patients with aortic stenosis undergoing trans catheter aortic valve replacement., Aortic stenosis is a narrowing of the aortic valve opening, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
| Not yet recruiting | 3 | 430 | Europe | Forxiga 10 mg (Dapagliflozin), 0310-6205-30, Buccal tablet, Forxiga 10 mg (Dapagliflozin) | Oslo University Hospital, Oslo University Hospital, Skåne University Hospital, Sahlgrenska University Hospital, Rigshospitalet, Aarhus University Hospital, Erasmus MC | heart transplant recipients in follow-up, heart transplant recipients in follow-up, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
NCT04255238: A Study to Evaluate the Efficacy and Safety of Dual add-on Therapy With Gemigliptin 50 mg and Dapagliflozin 10 mg Added to Metformin Who Have Inadequate Glycemic Control on Metformin Alone |
|
|
| Not yet recruiting | 3 | 468 | NA | Gemigliptin 50mg, Zemiglo tab 50mg, Dapagliflozin 10mg, Forxiga tab 10mg | LG Chem | Diabetes Mellitus, Type 2 | 05/22 | 12/22 | | |
NCT05109949: Acute Effect of Empagliflozin vs Dapagliflozin Over Pulse Wave Velocity in Type Two Diabetes |
|
|
| Active, not recruiting | 3 | 72 | RoW | Dapagliflozin 10Mg Tab, Farxiga, Forxiga, Empagliflozin 25 MG, Jardiance, Placebo | Centro Universitario de Ciencias de la Salud, Mexico | Diabetes Mellitus Type 2 Without Complication | 06/22 | 08/22 | | |
2021-005446-15: A Randomized Controlled Clinical Trial to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients with Severe Chronic Kidney Disease Een placebo gecontroleerde studie om het effect van dapagliflozine op nier- en hartfalen te onderzoeken bij nierpatiënten |
|
|
| Not yet recruiting | 3 | 1500 | Europe | Dapagliflozin, Tablet, Forxiga | University Medical Center Groningen, AstraZeneca, Dutch Kidney Foundation | Combined endpoint of all-cause mortality, kidney failure, and hospitalization for heart failure in the overall study population, Combined endpoint of all-cause mortality, kidney failure, and hospitalization for heart failure in the overall study population, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
| Recruiting | 3 | 28 | US | Dapagliflozin 10Mg Tab, Placebo | University of Oklahoma | Diabetes Mellitus, Atrial Fibrillation | 04/25 | 04/25 | | |
NCT04885712: A Study to Evaluate the Efficacy and Safety of Pioglitazone 15mg or 30mg Add-on in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin |
|
|
| Completed | 3 | 378 | RoW | Metformin≥1000mg, BR3003D, Pioglitazone 15mg, BR3003A-1, Pioglitazone 30 mg, BR3003B-1, Pioglitazone 15mg Placebo, BR3003A-2, Pioglitazone 30mg Placebo, BR3003B-2, Dapagliflozin 10mg, BR3003C | Boryung Pharmaceutical Co., Ltd | Type2 Diabetes | 09/22 | 03/23 | | |
NCT05159882: Safety and Efficacy of THR-1442 Compared to Dapagliflozin as Add-on Therapy to Metformin in T2DM |
|
|
| Recruiting | 3 | 390 | RoW | THR-1442 and Dapagliflozin placebo, Dapagliflozin 10mg and THR1442 placebo | Newsoara Biopharma Co., Ltd. | T2DM | 09/22 | 09/22 | | |
NCT06142474: SGLT2 Inhibitors in Patients With ADHF During Ventilator Weaning |
|
|
| Recruiting | 3 | 450 | RoW | SGLT2 inhibitor, Empagliflozin and dapagliflozin | National Taiwan University Hospital | Heart Failure Acute, Ventilator Lung | 10/30 | 10/30 | | |
| Active, not recruiting | 3 | 61 | Europe | Dapagliflozin 10 MG Oral Tablet, dapagliflozin, Metolazone Tablets, metolazone | NHS Greater Glasgow and Clyde, University of Glasgow | Heart Failure | 10/22 | 04/23 | | |
NCT05226897: Clinical Trial to Assess the Efficacy and Safety of YYC405 in Type 2 Diabetes Patients |
|
|
| Active, not recruiting | 3 | 256 | RoW | YYC405-T, Metformin≥1000mg, Dapagliflozin 10mg, YYC405-T placebo | Yooyoung Pharmaceutical Co., Ltd. | Type 2 Diabetes | 10/22 | 06/23 | | |
NCT05101135: To Evaluate the Efficacy and Safety of JT-001 add-on in Paatients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin |
|
|
| Recruiting | 3 | 256 | RoW | JT-001, JT-001 Placebo | Jeil Pharmaceutical Co., Ltd. | Type 2 Diabetes Mellitus | 10/22 | 10/22 | | |
| Recruiting | 3 | 52 | Europe | Dapagliflozin 10Mg Tab, Placebo | Andrea Giaccari | Type2 Diabetes Mellitus, Stable Coronary Artery Disease | 12/22 | 12/22 | | |
NCT05591235: Effect of Metformin, Dapagliflozin, Combination of Metformin and Pioglitazone in Patients With Type 2 Diabetes |
|
|
| Not yet recruiting | 3 | 60 | NA | Metformin, Dapagliflozin, Fixed-dose combination of metformin and pioglitazone (500mg metformin plus 15mg pioglitazone) | Nanjing First Hospital, Nanjing Medical University | Type2diabetes, Insulin Resistance | 12/22 | 02/23 | | |
NCT05998525: Dapagliflozin Effects on Coronary Calcium and Epicardial Fat Assessed by Cardiotomography |
|
|
| Completed | 3 | 54 | RoW | Dapagliflozin 10Mg Tab, Forxiga, Placebo, Placebo pill | Hilda Elizabeth Macías Cervantes | Diabete Type 2, Unstable Angina, Myocardial Infarction, Diabetes Mellitus, Type 2 | 12/22 | 06/23 | | |
2022-000596-40: Effect of dapagliflozin on blood magnesium levels in patients with low magnesium due to HNF1beta-associated kidney disease Het effect van dapagliflozine op het magnesiumgehalte bij patiënten met een laag magnesium door HNF1beta-geassocieerde nierziekte |
|
|
| Not yet recruiting | 3 | 12 | Europe | Tablet, Forxiga | Radboudumc, Dutch Kidney Foundation, AstraZeneca | Renal hypomagnesemia in ADTKD-HNF1β patients Renale hypomagnesiëmie bij ADTKD-HNF1β patiënten, Low magnesium levels in patients with HNF1beta-associated kidney disease Laag magnesiumgehalte bij patiënten met een HNF1beta geassocieerde nierziekte, Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | | | | |
NCT03199053 / 2015-005042-66: Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years Old |
|
|
| Completed | 3 | 256 | Europe, Canada, US, RoW | Dapagliflozin, Forxiga, Saxagliptin, Onglyza, Placebo | AstraZeneca | Diabetes Mellitus, Type 2 | 02/23 | 01/24 | | |
ChiCTR1800014345: The preventive effect of improving high filtration in subclinical stage on diabetic nephropathy: a prospective, multicenter cohort study |
|
|
| Recruiting | 3 | 120 | | dapagliflozin ;Losartan ;Empagliflozin | Tianjin Metabolic Diseases Hospital & Tianjin Medical University; Tianjin Medical University Metabolic Diseases Hospital, Tianjin Medical University | diabetic nephropathy | | | | |
| Completed | 3 | 162 | Europe | Dapagliflozin | Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia, Spanish Society of Cardiology | Heart Failure | 03/23 | 03/23 | | |
NCT04049110: Dapagliflozin in Physical Exercise in Type 1 Diabetes |
|
|
| Completed | 3 | 39 | Europe | Forxiga 10mg, Dapagliflozin, Placebo | Insel Gruppe AG, University Hospital Bern | Diabetes Mellitus, Type 1 | 04/23 | 05/23 | | |
ATTEMPT, NCT04333823: Adolescent Type 1 Diabetes Treatment With SGLT2i for hyperglycEMia & hyPerfilTration Trial |
|
|
| Active, not recruiting | 3 | 100 | Canada, US | Dapagliflozin 5mg, FORXIGA 5mg, ATC Code: A10BK01, DIN: 02435462, Placebo, Placebo (for Dapagliflozin) | The Hospital for Sick Children, Canadian Institutes of Health Research (CIHR), Juvenile Diabetes Research Foundation | Diabetes Mellitus, Type 1 | 05/24 | 05/24 | | |
NCT05310916: Effect of SGLT2i on Diabetic Retinopathy in Type 2 Diabetes Mellitus Patients |
|
|
| Recruiting | 3 | 60 | RoW | Dapagliflozin 10mg Tab plus another oral hypoglycemic agent, Diglifloz 10mg Tab, Two oral hypoglycemic agents other than dapagliflozin, Oral anti-diabetic agents | Nidae Alaa | Diabetic Retinopathy | 05/23 | 11/23 | | |
| Completed | 3 | 240 | US | Dapagliflozin 10 MG, sodium-glucose cotransporter-2(SGLT2) inhibitors, Protocolized Diuretic Therapy | Vanderbilt University Medical Center, AstraZeneca | Heart Failure, Diabetes Mellitus, Type 2 | 05/23 | 05/23 | | |
| Not yet recruiting | 3 | 36 | RoW | Dapagliflozin | Universitas Sebelas Maret | Rheumatic Heart Disease, Heart Failure, Mitral Stenosis | 05/23 | 06/23 | | |
NCT05308160: A Single Center, Randomized, Open Label, Parallel Group, Phase 3 Study to Evaluate the Efficacy of Dapagliflozin in Subjects With Nonalcoholic Fatty Liver Disease |
|
|
| Recruiting | 3 | 75 | RoW | Dapagliflozin 10Mg Tab, Placebo | National Taiwan University Hospital | Fatty Liver | 06/23 | 04/24 | | |
| Completed | 3 | 4017 | Europe | Dapagliflozin, Forxiga TM, Farxiga TM, Placebo | AstraZeneca, Uppsala University | Acute Myocardial Infarction, Heart Failure | 07/23 | 07/23 | | |
| Active, not recruiting | 3 | 380 | Europe, US, RoW | sparsentan, RE-021, irbesartan, Irbesartan Tablets USP, Dapagliflozin | Travere Therapeutics, Inc., Retrophin, Inc. | Immunoglobulin A Nephropathy | 08/23 | 07/26 | | |
| Not yet recruiting | 3 | 225 | NA | Dapagliflozin, Integrated CKD care program | Kaohsiung Medical University | Chronic Kidney Diseases | 08/23 | 09/23 | | |
| Completed | 3 | 507 | RoW | Dapagliflozin 10mg Tab, Farxiga, Standard of Care | Hospital Israelita Albert Einstein | Critical Illness, Sepsis | 10/23 | 10/23 | | |
NCT05296044: To Evaluate the Efficacy and Safety of JT-003 add-on in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin |
|
|
| Recruiting | 3 | 245 | RoW | JT-003, JT-003 Placebo | Jeil Pharmaceutical Co., Ltd. | Type 2 Diabetes Mellitus | 10/23 | 02/24 | | |
NCT05957887: Short and Intermediate Term Effect of Dapagliflozin on Left Ventricular Remodeling in Anterior STEMI Patients |
|
|
| Recruiting | 3 | 120 | RoW | Dapagliflozin | Mohamed Nabil Elkholy | STEMI | 03/25 | 04/25 | | |
ACHIEVE-2, NCT06192108: A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin |
|
|
| Recruiting | 3 | 888 | Europe, US, RoW | Orforglipron, LY3502970, Dapagliflozin | Eli Lilly and Company | Type 2 Diabetes | 10/25 | 10/25 | | |
NCT05849766: Effect of Dapagliflozin on Secondary Mitral Regurgitation |
|
|
| Recruiting | 3 | 150 | RoW | Dapagliflozin Farxiga®, Forxiga, Ramipril Tritace®, Carvedilol Carvid®,and Spironolactone Aldactone®, Tritace, Carvid, Aldactone | October 6 University, Beni-Suef University, National Heart Institute, Egypt | Dilated Cardiomyopathy | 02/24 | 05/24 | | |
| Not yet recruiting | 3 | 256 | Canada | Dapagliflozin 10mg Tab, CMR | Ottawa Heart Institute Research Corporation | ST Elevation Myocardial Infarction, Myocardial Infarction | 02/25 | 09/25 | | |
NCT05505994: The Efficacy and Safety of DWP16001 in Combination With Metformin in T2DM Patients Inadequately Controlled on Metformin |
|
|
| Active, not recruiting | 3 | 340 | RoW | DWP16001, DWP16001 tablet, Dapagliflozin, Dapagliflozin tablet, DWP16001 Placebo, DWP16001 Placebo tablet, Dapagliflozin Placebo, Dapagliflozin Placebo tablet | Daewoong Pharmaceutical Co. LTD. | Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders, Metabolic Disease, Endocrine System Diseases | 02/24 | 09/24 | | |
NCT06421870: Renoprotective Effects of Dapagliflozin Versus Pentoxiphylline in Chronic Kidney Disease Patients |
|
|
| Recruiting | 3 | 210 | RoW | Dapagliflozin 10mg Tab, Pentoxifylline 400 MG | Ain Shams University | Chronic Kidney Diseases | 05/25 | 07/25 | | |
NCT06268873: A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure. |
|
|
| Recruiting | 3 | 2500 | Europe, Canada, Japan, US, RoW | Baxdrostat/dapagliflozin, Baxdrostat CIN-107, Dapagliflozin in combination with placebo | AstraZeneca | Chronic Kidney Disease and Hypertension | 12/27 | 12/27 | | |
BalanceD-HF, NCT06307652: Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function |
|
|
| Recruiting | 3 | 4800 | Europe, Canada, Japan, US, RoW | balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg, balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg, dapagliflozin 10 mg and matching placebo for balcinrenone/dapagliflozin | AstraZeneca | Heart Failure and Impaired Kidney Function | 06/27 | 06/27 | | |
PROTECTAA, NCT06304857: CardioPROTECTion With Dapagliflozin in Breast Cancer Patients Treated With AnthrAcycline - TRIAL |
|
|
| Recruiting | 3 | 188 | Europe | Dapagliflozin, Farxiga, Forxiga, Placebo | 4th Military Clinical Hospital with Polyclinic, Poland | Breast Cancer, Heart Failure | 12/26 | 12/27 | | |
NCT06415773: Effects of Berberine Ursodeoxycholate (HTD1801) Versus Dapagliflozin in Patients With Type 2 Diabetes Inadequately Controlled With Metformin |
|
|
| Recruiting | 3 | 418 | RoW | HTD1801, Berberine Ursodeoxycholate, Dapagliflozin | HighTide Biopharma Pty Ltd, Shenzhen HighTide Biopharmaceutical Ltd. | T2DM (Type 2 Diabetes Mellitus) | 07/25 | 09/25 | | |
COMBINED-HF, NCT06434025: IV Iron and SGLT2 Inhibitor on Ventricular Function and Myocardial Iron Content in Heart Failure With Iron Deficiency |
|
|
| Not yet recruiting | 3 | 99 | RoW | Iron Carboxymaltose, Ferinject, Dapagliflozin 10mg Tab, Forxiga, Placebo of Iron Carboxymaltose, Saline, Placebo of Dapagliflozin | Hospital de Clinicas de Porto Alegre, Vifor Pharma | Heart Failure, Systolic, Iron Deficiencies | 05/26 | 11/26 | | |
| Recruiting | 3 | 52 | Canada | Dapagliflozin 10 MG Oral Tablet, Placebo Matching Dapagliflozin Oral Tablet | University Health Network, Toronto | Kidney Transplant Recipients, Post-transplant Diabetes Mellitus, Type 2 Diabetes | 06/24 | 06/24 | | |